Waterstone Capital Management

Waterstone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic and digestive diseases, with a specific emphasis on chronic hepatitis B and type 2 diabetes. Headquartered in Wuxi, China, with additional research facilities in the United States, the company leverages its expertise in small molecule chemistry to target significant unmet medical needs. The company's lead candidate, WS-007, is a novel anti-viral agent in Phase 2 clinical trials for the treatment of hepatitis B. Additionally, Waterstone is advancing a pipeline of oral small-molecule GLP-1 receptor agonists, such as WS-008, designed to provide more convenient and effective options for patients with metabolic disorders. The firm is backed by prominent investors including Qiming Venture Partners and IDG Capital.